Common hepatitis C drugs available in Canada for adults

Treatments for all genotypes

Brand name (generic name)

Genotypes

Image

Dosage schedule

Food requirements

Weeks of treatment

Epclusa
(velpatasvir + sofosbuvir)

with or without ribavirin*

All

One tablet once daily

No food restrictions

12

Maviret
(glecaprevir + pibrentasvir)

All

Three tablets once daily

Take with food

8, 12 or 16

Treatments for specific genotypes

Brand name (generic name)

Genotypes

Image

Dosage schedule

Food requirements

Weeks of treatment

Harvoni
(ledipasvir + sofosbuvir)

1a, 1b, 4, 5, 6

One tablet once daily

No food restrictions

8 or 12

Zepatier
(elbasvir + grazoprevir)

with or without ribavirin*

1a, 1b, 4

One tablet once daily

No food restrictions

8, 12 or 16

Treatment after a previous course of direct-acting antiviral treatment

Brand name (generic name)

Genotypes

Image

Dosage schedule

Food requirements

Weeks of treatment

Vosevi
(sofosbuvir + velpatasvir
+ voxilaprevir)

All

One tablet once daily

Take with food

12

*ribavirin as a possible treatment addition

Ibavyr
(ribavirin)


1,000 mg for under 75 kg and 1,200 mg for 75 kg or more, twice daily

Take with food

See above

 

NOTE

This chart is not a complete list of Health Canada-approved treatments for hepatitis C. This chart lists common daily dosing schedules. People should always follow the dosing schedule prescribed by their healthcare provider. Healthcare providers can check for drug interactions between hepatitis C treatment and other drugs a person is taking with a pharmacist or at www.hep-druginteractions.org.

Disclaimer

Information provided by CATIE is not medical advice. Decisions about medical treatments should always be made in consultation with a medical practitioner knowledgeable about HIV and hepatitis C. CATIE endeavours to provide the most up-to-date and accurate information at the time of publication. However, information changes and users are encouraged to ensure they have the most current information. Any opinions expressed herein may not reflect the opinions of CATIE, its partners or funders.

Acknowledgements

Epclusa®, Harvoni® and Vosevi™ are trademarks of Gilead Sciences, Inc., or its related companies. Images of Epclusa, Harvoni and Vosevi, copyright Gilead Sciences, Inc., or its related companies. Used with permission. Maviret™ is a trademark of AbbVie Corporation. Image of Maviret is copyright AbbVie Corporation. Used with permission. Zepatier® is a registered trademark of Merck & Co, Inc. Image of Zepatier, copyright Merck & Co., Inc. Used with permission. Ibavyr™ is a trademark of Pharmascience Inc. Images used with permission.

Production of this publication has been made possible in part through financial contributions from the Ontario Ministry of Health and the Public Health Agency of Canada (PHAC). The views expressed herein do not necessarily represent the views of our funders.